Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ossium Health, Inc.
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Chengdu Zenitar Biomedical Technology Co., Ltd
Memorial Sloan Kettering Cancer Center
Prescient Therapeutics, Ltd.
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
UNC Lineberger Comprehensive Cancer Center
Columbia University
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Soligenix
City of Hope Medical Center
Mayo Clinic
Treeline Biosciences, Inc.
Assistance Publique - Hôpitaux de Paris
Mayo Clinic
Kyowa Kirin Co., Ltd.
Columbia University
SciTech Development, Inc.
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
Kyowa Kirin Co., Ltd.
Assistance Publique - Hôpitaux de Paris
University of Alabama at Birmingham
Ohio State University Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
Boston Immune Technologies and Therapeutics
UNC Lineberger Comprehensive Cancer Center
Beijing GoBroad Hospital
Case Comprehensive Cancer Center
City of Hope Medical Center
Mayo Clinic
Beijing GoBroad Hospital
Thomas Jefferson University
City of Hope Medical Center
Fox Chase Cancer Center
City of Hope Medical Center
Yale University
Bio-Path Holdings, Inc.